亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

207-OR: Myostatin Inhibition Synergizes with GLP-1R Agonism to Accelerate Weight Loss in Male, Obese Nonhuman Primates

肌生成抑制素 内科学 减肥 内分泌学 封锁 脂肪团 医学 瘦体质量 脂肪组织 2型糖尿病 骨骼肌 肥胖 受体 体重 糖尿病
作者
Jason Mastaitis,Daniel R. Gomez,Valerie Le Rouzic,Michael J. Stec,NAVEEN KHAN,Erqian Na,Toya McWilliams,Soo Min,MARK SLEEMAN
出处
期刊:Diabetes [American Diabetes Association]
卷期号:72 (Supplement_1) 被引量:9
标识
DOI:10.2337/db23-207-or
摘要

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become standard-of-care for the pharmacological treatment of obesity by inducing clinically meaningful weight loss through a reduction in appetite. While these agents potently reduce fat mass, the caloric restriction also reduces skeletal muscle mass. Strategies to preserve skeletal muscle in the presence of caloric restriction are needed to improve weight loss quality in obese patents. Trevogrumab (∝-MSTN) and garetosmab (∝-ActA) are fully human monoclonal antibodies that potently inhibit two mediators of skeletal muscle atrophy: myostatin (MSTN) and activin A (ActA). We first tested the effects of ∝-MSTN, ∝-ActA and GLP-1RA (Semaglutide [Sema]) on body composition of diet-induced obese mice either alone or in combination. Sema (-29.8%) and ∝-MSTN/∝-ActA (-23.4%) produced significant reduction in fat mass after 4 weeks of treatment vs baseline. Adding MTSN and ActA blockade to Sema produced an additive effect on fat mass (-54.2%). This combination also increased lean mass by 9.8% vs a 1.9% loss with Sema alone. To test this in primates, we performed a 20-week study with the combined administration of either Sema + ∝-MSTN or Sema + ∝-MSTN and ∝-ActA in obese male cynomolgus monkeys. The combination of ∝-MSTN + Sema was sufficient to cause an additive effect on fat mass -43.9% vs -25.1% for Sema alone. The addition of ∝-ActA to the combination produced a similar reduction in fat (-49.6%). The Sema control group also lost -2.5% lean mass after 20 weeks; despite the significant reduction in fat mass, the addition of ∝-MSTN to Sema slightly increased lean mass over the same period (0.5%); the addition of ∝-ActA increased lean mass even further (6.2%). These data suggest the blockade of MSTN and ActA to GLP-1RA treatment could greatly improve the quality of weight loss with this class of anti-obesity agents. Disclosure J.Mastaitis: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. D.Gomez: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. V.Le rouzic: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. M.Stec: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. N.Khan: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. E.Na: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. T.Mcwilliams: None. S.Min: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. M.Sleeman: Employee; Regeneron Pharmaceuticals Inc. Funding Regeneron Pharmaceuticals Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
花痴的善若完成签到,获得积分10
2秒前
6秒前
高兴夏之完成签到,获得积分10
7秒前
脑洞疼的应助被美满惜雪采纳,获得10
9秒前
Ava的应助被科研通管家采纳,获得10
10秒前
斯文败类的应助被科研通管家采纳,获得10
10秒前
Crssss的应助被科研通管家采纳,获得20
11秒前
Crssss的应助被科研通管家采纳,获得20
11秒前
小马甲的应助被wzrm采纳,获得10
11秒前
爱听歌鲂完成签到,获得积分10
21秒前
JamesPei的应助被YCLING采纳,获得10
30秒前
jj完成签到 ,获得积分10
30秒前
结实寒风完成签到,获得积分10
31秒前
烟花的应助被moriaty采纳,获得20
32秒前
腼腆钵钵鸡完成签到 ,获得积分10
34秒前
40秒前
YCLING发布了新的文献求助10
43秒前
bzchen完成签到 ,获得积分10
50秒前
50秒前
Jazz5688关注了科研通微信公众号
51秒前
CipherSage的应助被szxa采纳,获得10
51秒前
初景发布了新的文献求助10
56秒前
寻浣完成签到 ,获得积分10
58秒前
脑洞疼的应助被野猪佩奇采纳,获得10
1分钟前
黎笛完成签到,获得积分10
1分钟前
Akim的应助被刻苦乐天采纳,获得10
1分钟前
今天努力学习了吗完成签到,获得积分10
1分钟前
侯敬远完成签到 ,获得积分10
1分钟前
认真大娘完成签到,获得积分10
1分钟前
paradox完成签到 ,获得积分10
1分钟前
1分钟前
简单的语风完成签到,获得积分10
1分钟前
1分钟前
大壮完成签到,获得积分10
1分钟前
1分钟前
gzghgzh发布了新的文献求助10
1分钟前
1分钟前
美满惜雪发布了新的文献求助10
1分钟前
酷炫鹏煊完成签到 ,获得积分10
1分钟前
hyper完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184932
求助须知:如何正确求助?哪些是违规求助? 9573870
关于积分的说明 21833572
捐赠科研通 7782362
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558650
邀请新用户注册赠送积分活动 2481161